Development of Highly Selective Epoxyketone-based Plasmodium Proteasome Inhibitors with Negligible Cytotoxicity
biorxiv(2022)
摘要
Here we present remarkable epoxyketone-based proteasome inhibitors with low nanomolar in vitro potency for blood-stage Plasmodium falciparum and low cytotoxicity for human cells. Our best compound has more than 2,600-fold greater selectivity for erythrocytic-stage P. falciparum over HepG2 cells, which is largely driven by the accommodation of the parasite proteasome for a d-amino acid in the P3 position and the preference for a difluorobenzyl group in the P1 position. These compounds also significantly reduce parasitemia in a P. berghei mouse infection model and prolong survival of animals by an average of 6 days. The current epoxyketone inhibitors are ideal starting compounds for orally bioavailable anti-malarial drugs.
### Competing Interest Statement
The authors have declared no competing interest.
* Leu
: Leucine
Phe
: Phenylalanine
EK
: Epoxyketone
t -butyl
: tertiary-butyl
c20S
: human constitutive 20S
Pf20S
: P. falciparum 20S
IP
: intraperitoneal
IV
: intravenous
PK
: pharmacokinetics
SI
: selectivity index
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要